Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;14(2):167-182.
doi: 10.1111/jdi.13915. Epub 2022 Oct 19.

Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations

Jaime A Davidson #  1 , Norlela Sukor #  2 , Fen-Lee Hew  3 , Mafauzy Mohamed  4 , Zanariah Hussein  5
Affiliations
Review

Safety of sodium-glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations

Jaime A Davidson et al. J Diabetes Investig. 2023 Feb.

Abstract

The prevalence of type 2 diabetes mellitus continues to increase in many Asian countries, with possible contributing factors, such as younger-onset disease, diabetes development at lower body mass index, higher visceral fat accumulation and poorer β-cell function, among Asian populations. Sodium-glucose cotransporter 2 inhibitors have been shown to confer favorable effects in type 2 diabetes mellitus patients, such as improved glycemic control, weight and blood pressure reduction, and importantly, cardiorenal benefits. Sodium-glucose cotransporter 2 inhibitors are generally well-tolerated, and have a well-defined safety profile based on evidence from numerous clinical trials and post-marketing pharmacovigilance reporting. To our knowledge, this review is the first to provide a comprehensive coverage of the adverse events of sodium-glucose cotransporter 2 inhibitors, as well as their management and counseling aspects for Asian type 2 diabetes mellitus populations.

Keywords: Safety; Sodium-glucose cotransporter 2 inhibitors; Type 2 diabetes.

PubMed Disclaimer

References

    1. International Diabetes Federation . IDF Diabetes Atlas, 9th edn. Brussels: International Diabetes Federation, 2019.
    1. Lim LL, Tan AT, Moses K, et al. Place of sodium‐glucose cotransporter‐2 inhibitors in east Asian subjects with type 2 diabetes mellitus: insights into the management of Asian phenotype. J Diabetes Complications 2017; 31: 494–503. - PubMed
    1. Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta‐analysis. Diabetes Care 2013; 36: 1789–1796. - PMC - PubMed
    1. Kalra S, Ghosh S, Aamir AH, et al. Safe and pragmatic use of sodium‐glucose co‐transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement. Indian J Endocrinol Metab 2017; 21: 210–230. - PMC - PubMed
    1. Yeung RO, Zhang Y, Luk A, et al. Metabolic profiles and treatment gaps in young‐onset type 2 diabetes in Asia (the JADE programme): a cross‐sectional study of a prospective cohort. Lancet Diabetes Endocrinol 2014; 2: 935–943. - PubMed